SCHEMBL4436720

SCHEMBL4436720

CNC(=O)c1ccc2c(c1)CC(=O)N2C1CCN(CC(=O)N2CCC3(CC2)CC3)CC1

nearest known ligand 0.43

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
PLD1 Q13393 1/20 0.43
KCNH2 Q12809 3/20 0.40
CHRM4 P08173 2/20 0.40
HSD11B1 P28845 1/20 0.39
OPRM1 P35372 4/20 0.37
OPRL1 P41146 4/20 0.37
OPRK1 P41145 3/20 0.37
TNKS O95271 1/20 0.37
PARP1 P09874 1/20 0.37
PARP2 Q9UGN5 1/20 0.37
SMYD3 Q9H7B4 2/20 0.37
SCN1A P35498 1/20 0.36
SCN5A Q14524 1/20 0.36
SCN9A Q15858 1/20 0.36
KMT2A Q03164 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4446730 0.93 PLD1 (0.43) PLD1KCNH2CHRM4HSD11B1OPRM1
Hydrochloric Acid SCHEMBL4436857 0.92 PLD1 (0.42) PLD1KCNH2CHRM4HSD11B1OPRM1
SCHEMBL4440650 0.90 CHRM4 (0.41) PLD1KCNH2CHRM4HSD11B1OPRM1
SCHEMBL4437940 0.89 OPRL1 (0.45) PLD1KCNH2CHRM4HSD11B1OPRM1
Hydrochloric Acid SCHEMBL4555075 0.89 CHRM4 (0.41) PLD1KCNH2CHRM4HSD11B1OPRM1
SCHEMBL4438978 0.85 PLD1 (0.43) PLD1KCNH2CHRM4HSD11B1OPRM1
SCHEMBL4436741 0.85 PLD1 (0.43) PLD1KCNH2CHRM4HSD11B1OPRM1
SCHEMBL4443247 0.85 PLD1 (0.43) PLD1KCNH2CHRM4HSD11B1OPRM1
Hydrochloric Acid SCHEMBL4439105 0.85 PLD1 (0.42) PLD1KCNH2CHRM4HSD11B1OPRM1
SCHEMBL4437442 0.84 PLD1 (0.38) PLD1KCNH2CHRM4HSD11B1OPRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2121656-A1 INHIBITORS OF SERINE PALMITOYLTRANSFERASE Pfizer Products Inc. (US) 2009-11-25 EP claimed
US-20080287479-A1 INHIBITORS OF SERINE PALMITOYLTRANSFERASE PFIZER INC 2008-11-20 US claimed
WO-2008084300-A1 INHIBITORS OF SERINE PALMITOYLTRANSFERASE PFIZER PRODUCTS INC. (US) 2008-07-17 WO claimed
EP-2121656-A1 INHIBITORS OF SERINE PALMITOYLTRANSFERASE Pfizer Products Inc. (US) 2009-11-25 EP disclosed
US-20080287479-A1 INHIBITORS OF SERINE PALMITOYLTRANSFERASE PFIZER INC 2008-11-20 US disclosed
US-20080287479-A1 INHIBITORS OF SERINE PALMITOYLTRANSFERASE PFIZER INC 2008-11-20 US disclosed
US-20080287479-A1 INHIBITORS OF SERINE PALMITOYLTRANSFERASE PFIZER INC 2008-11-20 US disclosed
WO-2008084300-A1 INHIBITORS OF SERINE PALMITOYLTRANSFERASE PFIZER PRODUCTS INC. (US) 2008-07-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080287479-A1 INHIBITORS OF SERINE PALMITOYLTRANSFERASE SPTLC1, SPTLC2, CPT1A PLD1 351/4885KCNH2 4650/4885CHRM4 4343/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.